Check-CapSTU:7CC -0.96%30 EBIT per Share is €0.53 as of Dec. 2025. GuruFocus rates STU:7CC with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 167 Medical Diagnostics & Research companies, Check-Cap ranks better than 85.63% on this metric.
Check-Cap's EBIT per Share for the
six
months ended in Dec. 2025 was €0.73.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.53.
During the past 3 years, the average EBIT per Share Growth Rate was 52.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 41.60% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 46.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Check-Cap's EBIT per Share or its related term are showing as below:
STU:7CC'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -17 Med: 38.4 Max: 59.6
Current: 52.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Check-Cap was 59.60% per year. The lowest was -17.00% per year. And the median was 38.40% per year.
STU:7CC's 3-Year EBIT Growth Rate is ranked better than 85.63% of 167
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.2
vs STU:7CC: 52.40
Check-Cap's EBIT for the
six
months ended in Dec. 2025 was €4.83 Mil.
Check-Cap (STU:7CC) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Check-Cap EBIT per Share Related Terms
Check-Cap EBIT per Share Historical Data
* Premium members only.
The historical data trend for Check-Cap's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.53
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Check-Cap (STU:7CC) has a EBIT per Share of €0.53 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Check-Cap and its competitors. According to the industry distribution chart, Check-Cap ranks #24 out of 167 companies in the Medical Diagnostics & Research industry, placing it in the top 14.4%.
Is Check-Cap's EBIT per Share too high?
Check-Cap's current EBIT per Share is €0.53. Based on the distribution chart, Check-Cap ranks #24 out of 167 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Check-Cap has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Check-Cap's EBIT per Share compare to ADVB and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Check-Cap ranks #24 out of 167 companies for EBIT per Share. This places Check-Cap in the top 14% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 13.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.20, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Check-Cap and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Check-Cap's current EBIT per Share is €0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Check-Cap stock overvalued right now?
Check-Cap (STU:7CC) has a current EBIT per Share of €0.53. The current EBIT per Share is €0.53. Check-Cap's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Check-Cap (STU:7CC), the current EBIT per Share is €0.53 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.
30GF Score
Get the complete analysis for STU:7CC
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7CC has been successfully added to your 
